We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
Read MoreHide Full Article
GSK (GSK - Free Report) and Pfizer (PFE - Free Report) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their respiratory syncytial virus (RSV) vaccines.
The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying medical conditions like obesity, cardiovascular disease, diabetes, chronic obstructive pulmonary disorder (COPD), asthma and other chronic illnesses are at increased risk of RSV disease.
The updated ACIP recommendation expands the committee’s previous vote issued last June, which recommended the use of RSV vaccines for all adults aged 75 years. However, for those aged between 60 and 74, the ACIP recommended the vaccines for individuals at a higher risk of severe RSV disease due to underlying medical conditions.
The updated ACIP recommendation lowers the recommended age for RSV vaccination from 60 to 50 for high-risk adults.
The ACIP’s recommendation is pending final approval by the director of the CDC and the Department of Health and Human Services.
GSK's Price Performance
Year to date, shares of GSK have increased 4.6% against the industry’s decline of 6.6%.
Image Source: Zacks Investment Research
PFE's Price Performance
Year to date, shares of Pfizer have decreased 16.9% compared with the industry’s decline of 5.4%.
Image Source: Zacks Investment Research
Arexvy and Abrysvo are approved by the FDA for use in all individuals aged 60 and above. Arexvy is also approved for high-risk individuals aged 50-59, while Abrysvo is approved for high-risk adults aged 18-59 in the United States.
GSK is currently conducting clinical studies on Arexvy for expanded use in adults aged 18 to 49 years.
Arexvy generated sales worth £590 million in 2024, while Abrysvo generated sales worth $755 million. Sales of both Arexvy and Abrysvo were impacted last year, mainly due to the revised recommendations for RSV vaccinations issued by the ACIP in June 2024.
Another vaccine maker, Moderna’s (MRNA - Free Report) RSV vaccine – mResvia – was approved last year by the FDA and the European Commission to prevent RSV-LRTD in older adults aged 60 years and above.
An FDA filing is currently under review, seeking the expanded use of Moderna’s vaccine in high-risk adults aged 18-59 years. A final decision is expected by June 12, 2025. MRNA is also working on expanding the vaccine’s use in pediatric populations.
Image: Bigstock
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
GSK (GSK - Free Report) and Pfizer (PFE - Free Report) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the expanded use of their respiratory syncytial virus (RSV) vaccines.
The ACIP has now recommended the use of GSK’s RSV vaccine, Arexvy, and PFE’s RSV vaccine, Abrysvo, in adults aged 50-59 who are at high risk of severe RSV disease. Individuals with underlying medical conditions like obesity, cardiovascular disease, diabetes, chronic obstructive pulmonary disorder (COPD), asthma and other chronic illnesses are at increased risk of RSV disease.
The updated ACIP recommendation expands the committee’s previous vote issued last June, which recommended the use of RSV vaccines for all adults aged 75 years. However, for those aged between 60 and 74, the ACIP recommended the vaccines for individuals at a higher risk of severe RSV disease due to underlying medical conditions.
The updated ACIP recommendation lowers the recommended age for RSV vaccination from 60 to 50 for high-risk adults.
The ACIP’s recommendation is pending final approval by the director of the CDC and the Department of Health and Human Services.
GSK's Price Performance
Year to date, shares of GSK have increased 4.6% against the industry’s decline of 6.6%.
Image Source: Zacks Investment Research
PFE's Price Performance
Year to date, shares of Pfizer have decreased 16.9% compared with the industry’s decline of 5.4%.
Image Source: Zacks Investment Research
Arexvy and Abrysvo are approved by the FDA for use in all individuals aged 60 and above. Arexvy is also approved for high-risk individuals aged 50-59, while Abrysvo is approved for high-risk adults aged 18-59 in the United States.
GSK is currently conducting clinical studies on Arexvy for expanded use in adults aged 18 to 49 years.
Arexvy generated sales worth £590 million in 2024, while Abrysvo generated sales worth $755 million. Sales of both Arexvy and Abrysvo were impacted last year, mainly due to the revised recommendations for RSV vaccinations issued by the ACIP in June 2024.
Another vaccine maker, Moderna’s (MRNA - Free Report) RSV vaccine – mResvia – was approved last year by the FDA and the European Commission to prevent RSV-LRTD in older adults aged 60 years and above.
An FDA filing is currently under review, seeking the expanded use of Moderna’s vaccine in high-risk adults aged 18-59 years. A final decision is expected by June 12, 2025. MRNA is also working on expanding the vaccine’s use in pediatric populations.
GSK & PFE's Zacks Rank
Both GSK and Pfizer currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.